ReviewInternational journal of hematology2016
The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies.
Review in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- PROTACs: Walking through hematological malignancies.Frontiers in pharmacology · 2023Review
- EZH2 regulates oncomiR-200c and EMT markers in esophageal squamous cell carcinomas.Scientific reports · 2022Article
- Mechanisms of Polycomb group protein function in cancer.Cell research · 2022Review
- Drosophila Hox genes induce melanized pseudo-tumors when misexpressed in hemocytes.Scientific reports · 2021Article
- Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.Journal of hematology & oncology · 2020Review
- Structural heterogeneity of the mammalian polycomb repressor complex in immune regulation.Experimental & molecular medicine · 2020Review
- Phc2 controls hematopoietic stem and progenitor cell mobilization from bone marrow by repressing Vcam1 expression.Nature communications · 2019Article
- Article
- ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.Cellular and molecular life sciences : CMLS · 2018Review
- Emerging EZH2 Inhibitors and Their Application in Lymphoma.Current hematologic malignancy reports · 2018Review
- High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.Leukemia · 2018Article
- Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Clinical epigenetics · 2018Review
- Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.Oncotarget · 2017Article
- Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Cancer science · 2017Article
- MiR-203 Interplays with Polycomb Repressive Complexes to Regulate the Proliferation of Neural Stem/Progenitor Cells.Stem cell reports · 2017Article
- Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.Cancer science · 2017Review
- Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.International journal of hematology · 2017Review
- Guest editorial: Cooperative networks for stem cell homeostasis in normal and malignant hematopoiesis: from metabolism to epigenetics.International journal of hematology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycomb group (PcG) proteins are epigenetic regulatory factors that maintain the repression of target gene expression through histone modification. PcG proteins control the repression of genes that regulate differentiation and the cell cycle in the maintenance of hematopoietic stem cells (HSC). Moreover, abnormalities in expression level and mutations in PcG genes have been reported in various types of cancer, including hematological malignancies. In this review, we present an overview of the roles of PcG proteins in HSC and various types of hematological malignancies.
Indexed as
Identifiers
27086351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.